Market Overview

PetMed Express D/B/A 1-800-PetMeds Announces Record Earnings for Its First Fiscal Quarter and Its Increased Quarterly Dividend of $0.27 Per Share

Share:

First Quarter Net Income Increased 36%

First Quarter Sales Increased 10%

First Quarter Diluted EPS $0.62 per share vs $0.45 per share

DELRAY BEACH, Fla., July 23, 2018 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ:PETS) today announced its financial results for the quarter ended June 30, 2018.  Net sales for the quarter ended June 30, 2018 were $87.4 million, compared to $79.7 million for the quarter ended June 30, 2017, an increase of 10%.  Reorder sales increased 11%, to $71.5 million for the quarter ended June 30, 2018, compared to $64.5 million for the same quarter in the prior year.  New order sales increased 4.6%, to $15.9 million for the quarter ended June 30, 2018, compared to $15.2 million for the same quarter in the prior year.  Net income was $12.6 million, or $0.62 diluted per share, for the quarter ended June 30, 2018, compared to net income of $9.3 million, or $0.45 diluted per share, for the quarter ended June 30, 2017, a 36% increase in net income.  The Company's online sales for the quarter ended June 30, 2018 were approximately 85% of all sales compared to 84% for the same quarter the prior year, with online sales increasing 12%.    

Menderes Akdag, President and CEO, commented: "We were pleased with increases in both new order and reorder sales during the quarter, along with continued net income growth.  This increase to net income can be attributed to increased revenues, which increased gross profit by $2.5 million.  In addition, our net income growth was boosted by the Tax Reform Act of 2017, due to a decline in our federal tax rate from 35% to 21%.  We expect our effective tax rate in fiscal 2019 to be approximately 24%.  Average order value increased to $90 for the quarter compared to $87 for the same quarter the prior year.  Net cash from operations for the quarter ended June 30, 2018 was $22.0 million, compared to $13.9 million for the same period last year. In fiscal 2019, we will look to build on past successes by focusing on sales growth and further improving our customer service levels."

The Board of Directors declared an increased quarterly dividend of $0.27 per share on the Company's common stock.  The dividend will be payable on August 10, 2018, to shareholders of record at the close of business on August 3, 2018.  The Company intends to continue to pay regular quarterly dividends; however, the declaration and payment of future dividends is discretionary and will be subject to a determination by the Board of Directors each quarter following its review of the Company's financial performance.

This morning at 8:30 A.M. Eastern Time, Mr. Akdag will host a conference call to review the quarter's financial results.  To access the call, which is open to the public, please dial (888) 455-1758 (toll free) or (203) 827-7025.  Callers will be required to supply PETMEDS as the passcode.  For those unable to participate in the live event, the call will be available for replay from 10:00 A.M. on July 23, 2018 until August 6, 2018 at 11:59 P.M.  To access the replay, call (888) 277-5024 (toll free) or (203) 369-3021, and enter passcode 5500.

Founded in 1996, PetMed Express is America's Largest Pet Pharmacy, delivering prescription and non-prescription pet medications and other health products for dogs and cats at competitive prices direct to the consumer through its 1-800-PetMeds toll free number and on the Internet through its website at www.1800petmeds.com.
                                                             
This press release may contain "forward-looking" statements, as defined in the Private Securities Litigation Reform Act of 1995 or by the Securities and Exchange Commission, that involve a number of risks and uncertainties, including the Company's ability to meet the objectives included in its business plan.  Important factors that could cause results to differ materially from those indicated by such "forward-looking" statements are set forth in Management's Discussion and Analysis of Financial Condition and Results of Operations in the PetMed Express Annual Report on Form 10-K for the year ended March 31, 2018.  The Company's future results may also be impacted by other risk factors listed from time to time in its SEC filings, including, but not limited to, the Company's Form 10-Q and its Annual Report on Form 10-K.  For investment relations contact PetMed Express, Inc., Bruce S. Rosenbloom, CFO, 561-526-4444. 

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except for per share amounts)
             
    June 30,     March 31,
    2018     2018
ASSETS   (Unaudited)      
           
Current assets:          
Cash and cash equivalents $   94,561   $   77,936
Accounts receivable, less allowance for doubtful accounts of $37 and $35, respectively     2,431       2,292
Inventories - finished goods     25,046       23,337
Prepaid expenses and other current assets     1,278       882
Prepaid income taxes     -        788
Total current assets     123,316       105,235
           
Noncurrent assets:          
Property and equipment, net     28,491       28,741
Intangible assets     860       860
Total noncurrent assets     29,351       29,601
           
Total assets $   152,667   $   134,836
           
LIABILITIES AND SHAREHOLDERS' EQUITY          
           
Current liabilities:          
Accounts payable $   21,182   $   15,274
Accrued expenses and other current liabilities     3,526       2,835
Income taxes payable     3,247       - 
Total current liabilities     27,955       18,109
           
Deferred tax liabilities     831       996
           
Total liabilities     28,786       19,105
           
Commitments and contingencies          
           
Shareholders' equity:          
Preferred stock, $.001 par value, 5,000 shares authorized; 3 convertible shares issued and outstanding with a liquidation preference of $4 per share     9       9
Common stock, $.001 par value, 40,000 shares authorized; 20,601 and 20,601 shares issued and outstanding, respectively     21       21
Additional paid-in capital     10,100       9,381
Retained earnings     113,751       106,320
           
Total shareholders' equity     123,881       115,731
           
Total liabilities and shareholders' equity $   152,667   $   134,836
           

 

 PETMED EXPRESS, INC. AND SUBSIDIARIES 
 CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME 
 (In thousands, except for per share amounts) (Unaudited) 
               
     Three Months Ended   
     June 30,   
    2018     2017  
             
 Sales   $    87,390    $    79,657  
 Cost of sales      57,436       52,192  
             
 Gross profit      29,954       27,465  
             
 Operating expenses:             
 General and administrative      6,934       6,226  
 Advertising      6,707       6,292  
 Depreciation      556       531  
 Total operating expenses      14,197       13,049  
             
 Income from operations      15,757       14,416  
             
 Other income:             
 Interest income, net      379       83  
 Other, net      317       241  
 Total other income      696       324  
             
 Income before provision for income taxes      16,453       14,740  
             
 Provision for income taxes      3,871       5,464  
             
 Net income   $    12,582    $    9,276  
             
 Comprehensive income   $    12,582    $    9,276  
             
 Net income per common share:             
 Basic   $    0.62    $    0.46  
 Diluted   $    0.62    $    0.45  
             
 Weighted average number of common shares outstanding:             
 Basic      20,408       20,293  
 Diluted      20,449       20,448  
             
 Cash dividends declared per common share   $    0.25    $    0.20  
             

 

PETMED EXPRESS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
 (In thousands) (Unaudited) 
                 
     Three Months Ended 
     June 30, 
    2018      2017 
 Cash flows from operating activities:           
 Net income   $    12,582      $    9,276  
 Adjustments to reconcile net income to net cash provided by operating activities:           
 Depreciation      556         531  
 Share based compensation      719         494  
 Deferred income taxes      (165 )       (104 )
 Bad debt expense      32         28  
 (Increase) decrease in operating assets and increase in liabilities:           
 Accounts receivable      (171 )       (279 )
 Inventories - finished goods      (1,709 )       (2,804 )
 Prepaid income taxes      788         -   
 Prepaid expenses and other current assets      (396 )       (494 )
 Accounts payable      5,908         984  
 Accrued expenses and other current liabilities      643         696  
 Income taxes payable      3,247         5,568  
 Net cash provided by operating activities      22,034         13,896  
           
 Cash flows from investing activities:           
 Purchases of property and equipment      (306 )       (43 )
 Net cash used in investing activities      (306 )       (43 )
           
 Cash flows from financing activities:           
 Dividends paid      (5,103 )       (4,058 )
 Net cash used in financing activities      (5,103 )       (4,058 )
           
 Net increase in cash and cash equivalents      16,625         9,795  
 Cash and cash equivalents, at beginning of period      77,936         58,730  
           
 Cash and cash equivalents, at end of period   $    94,561      $    68,525  
           
 Supplemental disclosure of cash flow information:           
           
 Dividends payable in accrued expenses   $    288      $    263  
           


View Comments and Join the Discussion!